Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

201 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

NLS Pharmaceutics to Present at the 35th Annual Roth Conference

March 01, 2023 at 08:30 AM EST

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

ZURICH, SWITZERLAND / ACCESSWIRE / March 1, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced Alex Zwyer, CEO, will be presenting at the 35th Annual Roth Conference.

NLS Pharmaceutics AG, Wednesday, March 1, 2023, Press release picture

Event	35th Annual Roth Conference
Date	March 13, 2023
Presentation	10:00 AM Pacific Time (1:00 PM Eastern Time)
Location	Dana Point, CA

This year's event will consist of 1-on-1 / small group meetings, analyst-selected fireside chats, thematic industry panels, and company presentations by executive management from approximately 400 private and public companies in a variety of growth sectors including: Business Services, Consumer / Health & Wellness, Healthcare, Resources: Oil & Gas / Metals & Mining, Technology, Media & AgTech and Sustainability/ESG.

To learn more and submit a registration request, visit https://ibn.fm/Roth2023Registration

The live audio webcast and replay will be available in the investor relations section of the Company's website at https://nlspharma.com/investors/events-and-presentations/

About ROTH MKM

ROTH MKM is a relationship-driven investment bank focused on serving growth companies and their investors. Our full service platform provides capital raising, high impact equity research, macroeconomics, sales and trading, technical insights, derivatives strategies, M&A advisory, and corporate access. Headquartered in Newport Beach, California, ROTH MKM is a privately-held, employee owned organization and maintains offices throughout the U.S. For more information, please visit www.roth.com.

About NLS Pharmaceutics Ltd.

NLS Pharmaceutics Ltd. (Nasdaq:NLSP) is a global development-stage biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system, or CNS, disorders, who have unmet medical needs. Headquartered in Switzerland and founded in 2015, NLS is led by an experienced management team with a track record of developing and commercializing product candidates. For more information, please visit www.nlspharma.com.

For additional information:

Marianne Lambertson (investors & media)
NLS Pharmaceutics Ltd.
+1 239.682.8500
ml@nls-pharma.com
www.nlspharmaceutics.com

SOURCE: NLS Pharmaceutics Ltd.

View source version on accesswire.com:
https://www.accesswire.com/741403/NLS-Pharmaceutics-to-Present-at-the-35th-Annual-Roth-Conference

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article